Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $139M | $199M | $193M | $261M | $338M | $467M | $451M | $433M | $482M | $564M |
| Revenue growth | — | 43.1% | -2.5% | 34.9% | 29.6% | 38.2% | -3.5% | -3.9% | 11.3% | 17.0% |
| Gross profit | $90.5M | $137M | $125M | $185M | $251M | $353M | $346M | $327M | $366M | — |
| Gross margin | 65.3% | 69.2% | 64.4% | 70.9% | 74.2% | 75.6% | 76.7% | 75.4% | 76.0% | — |
| Operating income | -$8.78M | -$5.49M | -$51.6M | -$29.9M | $26.7M | $72.2M | $22.3M | $12.5M | -$1.28M | $44.7M |
| Operating margin | -6.3% | -2.8% | -26.7% | -11.4% | 7.9% | 15.5% | 4.9% | 2.9% | -0.3% | 7.9% |
| Net income | -$17.0M | -$8.39M | -$64.8M | -$38.7M | $17.2M | $94.2M | $15.5M | $4.95M | $861K | $37.0M |
| Net margin | -12.2% | -4.2% | -33.5% | -14.8% | 5.1% | 20.2% | 3.4% | 1.1% | 0.2% | 6.6% |
| EPS (diluted) | -$0.27 | -$0.14 | -$0.94 | -$0.42 | $0.15 | $0.70 | $0.12 | $0.04 | -$0.01 | $0.15 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.87M | -$3.49M | -$60.6M | -$33.5M | $5.47M | $62.0M | $24.9M | $30.9M | $14.2M | -$10.3M |
| Capital expenditures | $1.36M | $2.43M | $1.86M | $5.98M | $17.7M | $31.2M | $33.9M | $24.4M | $10.0M | $14.2M |
| Free cash flow | -$6.23M | -$5.92M | -$62.5M | -$39.5M | -$12.2M | $30.8M | -$9.04M | $6.55M | $4.18M | -$24.5M |
| Share buybacks | — | — | — | — | — | — | $0.00 | $0.00 | $25.5M | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.86M | $2.36M | $21.4M | $60.4M | $84.4M | $114M | $102M | $104M | $136M | $93.7M |
| Total assets | $311M | $149M | $164M | $221M | $290M | $443M | $449M | $460M | $498M | $599M |
| Total liabilities | $11.3M | $157M | $117M | $165M | $148M | $202M | $184M | $181M | $113M | $165M |
| Long-term debt | — | $52.1M | — | $49.6M | $70.0M | $74.1M | $71.3M | $66.6M | — | — |
| Shareholders' equity | -$16.0M | -$15.3M | $39.9M | $52.0M | $142M | $241M | $266M | $279M | $263M | $300M |
| Retained earnings | -$234K | -$65.4M | -$130M | -$171M | -$155M | -$60.8M | -$45.3M | -$41.0M | -$40.1M | -$3.08M |
| Shares (wtd avg diluted) | — | 67.0M | 69.3M | 92.8M | 111M | 134M | 132M | 133M | 132M | 130M |
Every figure is extracted from Organogenesis Holdings Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.